Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Minimal Residual Disease in B-ALL and Clonal Analysis

Quantification of minimal residual disease in children with oligoclonal B-precursor acute lymphoblastic leukemia indicates that the clones that grow out during relapse already have the slowest rate of reduction during induction therapy

Leukemia volume 15, pages 134–140 (2001)Cite this article

Abstract

Antigen receptor gene rearrangements are applied for the PCR-based minimal residual disease (MRD) detection in acute lymphoblastic leukemia (ALL). It is known that ongoing rearrangements result in subclone formation, and that the relapsing subclone(s) can contain antigen receptor rearrangement(s) that differ from the rearrangements found in the major clone(s) at diagnosis. However, the mechanism leading to this so-called clonal evolution is not known, particularly at which time point in the disease the relapsing subclone obtains its (relative) therapy resistance. To obtain insight in clonal evolution, we followed the kinetics of several subclones in three oligoclonal ALL patients during induction therapy. Clone-specific nested PCR for immunoglobulin heavy chain or T cell receptor δ gene rearrangements were performed in limiting dilution assays on bone marrow samples taken at diagnosis, at the end of induction therapy and at possible relapse in three children with oligoclonal B-precursor ALL. We demonstrated that in all three patients the subclones were behaving differently in response to therapy. Moreover, in the two patients who relapsed, the clones that grew out during relapse showed the slowest regression or even evoluated during induction therapy and the clones that were not present at relapse showed good response to induction therapy. These results support the hypothesis that at least in some patients already at diagnosis or in the very first weeks, subclones have important differences in respect to resistance. Hence, these data give experimental evidence for the need to develop, during the first months after diagnosis, quantitative PCR assays for at least two different Ig/TCR gene rearrangement targets for every ALL patient.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Beishuizen A, Hahlen K, Hagemijer A, Verhoeven MA, Hooijkaas H, Adriaansen HJ, Wolvers Tettero IL, van Wering ER, Van Dongen JJ . Multiple rearranged immunoglobulin genes in childhood acute lymphoblastic leukemia of precursor B-cell origin Leukemia 1991 5: 657–667

    CAS  PubMed  Google Scholar 

  2. Steward CG, Goulden NJ, Katz F, Baines D, Martin PG, Langlands K, Potter MN, Chessels JM, Oakhill A . A polymerase chain reaction study of the stability of Ig heavy chain and T-cell receptor delta gene rearrangements between presentation and relapse of childhood B-lineage acute lymphoblastic leukemia Blood 1994 83: 1355–1362

    CAS  PubMed  Google Scholar 

  3. Beishuizen A, Verhoeven MA, van Wering ER, Hahlen K, Hooijkaas H, van Dongen JJ . Analysis of Ig and T-cell receptor genes in 40 childhood acute lymphoblastic leukemias at diagnosis and subsequent relapse. Implications for the detection of minimal residual disease by polymerase chain reaction analysis Blood 1994 83: 2238–2247

    CAS  PubMed  Google Scholar 

  4. Ghali DW, Panzer S, Fischer S, Argyriou-Tirita A, Haas OA, Kovar H, Gadner H, Panzer-Grumayer ER . Heterogeneity of the T-cell receptor delta gene indicating subclone formation in acute precursor B-cell leukemias Blood 1995 85: 2795–2801

    CAS  PubMed  Google Scholar 

  5. Steenbergen EJ, Verhagen OJ, van Leeuwen EF, van den Berg H, von dem Borne AEGKr, van der Schoot CE . Frequent ongoing T-cell receptor rearrangements in childhood B-precursor ALL: implications for monitoring minimal residual disease Blood 1995 86: 692–702

    CAS  PubMed  Google Scholar 

  6. Steenbergen EJ, Verhagen OJ, van Leeuwen EF, van den Berg H, Behrendt H, Slater RM, von dem Borne AEG Kr, van der Schoot CE . Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia Leukemia 1995 9: 1726–1734

    CAS  PubMed  Google Scholar 

  7. Steenbergen EJ, Verhagen OJ, van den Berg H, van Leeuwen EF, Behrendt H, Slater RR, von dem Borne AEG Kr, van der Schoot CE . Rearrangement status of the malignant cell determines type of secondary IgH rearrangement (V-replacement or V to DJ joining) in childhood B-precursor acute lymphoblastic leukemia Leukemia 1997 11: 1258–1265

    Article  CAS  PubMed  Google Scholar 

  8. Szczepanski AJ, Beishuizen A, Pongers-Willemse MJ, Hahlen K, Van Wering ER, Wijkhuis J, Tibbe GJ, De Bruijn MA, van Dongen JJ . Cross lineage T-cell receptor gene rearrangements occur in more than ninety percent of childhood B-precursor acute lymphoblastic leukemias: alternative PCR targets for detection of minimal residual disease Leukemia 1999 13: 196–205

    Article  CAS  PubMed  Google Scholar 

  9. Steenbergen EJ, Verhagen OJ, Nibbering CP, van den Berg H, van Leeuwen EF, Behrendt H, von dem Borne AEGKr, van der Schoot CE . Clonal evolution of immunoglobulin heavy chain rearrangements in childhood B-precursor acute lymphoblastic leukemia after engraftment in SCID mice Leukemia 1996 10: 1471–1478

    CAS  PubMed  Google Scholar 

  10. van den Berg H, Vet R, den Ouden E, Behrendt H . Significance of lymphoblasts in cerebrospinal fluid in newly diagnosed pediatric acute lymphoblastic malignancies with bone marrow involvement: possible benefit of dexamethasone Med Pediatr Oncol 1995 25: 22–27

    Article  CAS  PubMed  Google Scholar 

  11. Verhagen OJ, Wijkhuijs AJ, van der Sluijs-Gelling AJ, Szczepanski T, van der Linden-Schrever BE, Pongers-Willemse MJ, van Wering ER, van Dongen JJ, van der Schoot CE . Suitable DNA isolation method for the detection of minimal residual disease by PCR techniques Leukemia 1999 13: 1298–1299

    Article  CAS  PubMed  Google Scholar 

  12. Takahashi N, Nakai N, Honjo T . Cloning of human immunoglobulin δ gene and comparison with mouse δ gene Nucleic Acids Res 1980 8: 5983–5991

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Baer R, Boehm T, Yssel H, Rabbits TH . Complex rearrangements within the human Jδ-Cδ/Jαδ-Cα locus and aberrant recombination between Jα segments EMBO J 1988 7: 1661–1668

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Deane M, Norton JD . Immunoglobulin heavy chain variable region family usage is independent of tumor cell phenotype in human B lineage leukemias Eur J Immunol 1990 20: 2209–2217

    Article  CAS  PubMed  Google Scholar 

  15. Steenbergen EJ, Verhagen OJ, van Leeuwen EF, van den Berg H, Behrendt H, von dem Borne AE, van der Schoot CE . IGH/TCR delta PCR oligonucleotide liquid hybridization, a fast and sensitive assay for monitoring minimal residual disease in childhood B-precursor ALL Leukemia 1995 9: 216–222

    CAS  PubMed  Google Scholar 

  16. De Haas M, Kleijer M, Van Zwieten R, Roos D, von dem Borne AEGKr . Neutrophil FcγRIIIb deficiency, nature and clinical consequences: a study of 21 donors from 14 families Blood 1995 85: 2403–2413

    Google Scholar 

  17. Sykes PJ, Neoh SH, Brisco MJ, Hughes E, Condon J, Morley AA . Quantitation of targets for PCR by use of limiting dilution Biotechniques 1992 13: 444–449

    CAS  PubMed  Google Scholar 

  18. Ouspenskaia MV, Johnston DA, Roberts WM, Estrov Z, Zipf Th . Accurate quantitation of residual B-precursor acute lymphoblastic leukemia by limiting dilution and a PCR-based detection system: a description of the method and the principles involved Leukemia 1995 9: 321–328

    CAS  PubMed  Google Scholar 

  19. Taswell C . Limiting dilution assays for determination of immunocompetent cell frequencies J Immunol 1981 126: 1614–1619

    CAS  PubMed  Google Scholar 

  20. Fazekas de St Groth S . The evaluation of limiting dilution assays J Immunol Methods 1982 49: R11-R23

    Google Scholar 

  21. Strijbosch LWG, Does RJMM, Buurman WA . Computer aided design and evaluation of limiting and serial dilutions Int J Biomed Comput 1988 23: 279–290

    Article  CAS  PubMed  Google Scholar 

  22. Küppers R, Zhao M, Hansman M-L, Rajewski K . Tracing B-cell development in human germinal centres by molecular analysis of single cells picked from histological sections EMBO J 1993 12: 4955–4967

    Article  PubMed Central  PubMed  Google Scholar 

  23. Brisco MJ, Condon J, Hughes E, Neoh SH, Sykes PJ, Seshadri R, Toogood I, Waters K, Tauro G, Ekert H, Morley AA . Outcome prediction in childhood acute lymphoblastic leukemia by molecular quantification of residual disease at the end of induction Lancet 1994 343: 169–199

    Article  Google Scholar 

  24. Cavé H, Guidal C, Rohrlich P, Delfau MH, Broyart A, Lescoeur B, Rahimy C, Fennetau O, Monplaisir N, d'Auriol L . Prospective monitoring and quantification of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of δ and γ T-cell receptor genes Blood 1994 83: 1892–1902

    PubMed  Google Scholar 

  25. Dibenedetto SP, Lo Nigro L, Mayer SP, Rovera G, Schiliro G . Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia Blood 1997 90: 1226–1232

    CAS  PubMed  Google Scholar 

  26. Jacquy C, Delepaut B, Van Daele S, Vaerman JL, Zenebergh A, Brichard B, Vermylen C, Cornu G, Martiat P . A prospective study of minimal residual disease in childhood B-lineage acute lymphoblastic leukemia: MRD level at the end of induction is a strong predictive factor of relapse Br J Haematol 1997 98: 140–146

    Article  CAS  PubMed  Google Scholar 

  27. Foroni L, Coyle LA, Papaioannou M, Yaxley JC, Sinclair MF, Chim JS, Cannell P, Secker-Walker LM, Mehta AB, Prentice HG, Hoffbrand AV . Molecular detection of minimal residual disease in adult and childhood acute lymphoblastic leukemia reveals differences in treatment response Leukemia 1997 11: 1732–1741

    Article  CAS  PubMed  Google Scholar 

  28. Goulden NJ, Knechtli CJ, Carland RJ, Langlands K, Hancock JP, Potter MN, Steward CG, Oackhill A . Minimal residual disease analysis for the prediction of relapse in children with standard-risk acute lymphoblastic leukemia Br J Haematol 1998 1: 235–244

    Article  Google Scholar 

  29. Cavé H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, Bakkus M, Thielemans K, Grandchamp B, Vilmer E . Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia New Engl J Med 1998 339: 591–598

    Article  PubMed  Google Scholar 

  30. van Dongen JJM, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L, Stolz F, Schrappe M, Masera G, Kamps WA, Gadner H, van Wering ER, Ludwig WD, Basso G, de Bruijn MAC, Cazzaniga G, Hettinger K, van der Does-van den Berg A, Hop WCJ, Riehm H, Bartram CR . Prognostic value of minimal residual disease in acute lymphoblastic leukemia in childhood Lancet 1998 352: 1731–1738

    Article  CAS  PubMed  Google Scholar 

  31. Steenbergen EJ, Verhagen OJHM, van Leeuwen EF, von dem Borne AEGKr, van der Schoot CE . Distinct ongoing Ig heavy chain rearrangement processes in childhood B-precursor acute lymphoblastic leukemia Blood 1993 82: 581–589

    CAS  PubMed  Google Scholar 

  32. Green E, McConville CM, Powell JE, Mann JR, Darbyshire PJ, Taylor AMR, Stankovi T . Clonal diversity of Ig and T cell-receptor gene rearrangements identifies a subset of childhood B-precursor acute lymphoblastic leukemia with increased risk of relapse Blood 1998 92: 952–958

    CAS  PubMed  Google Scholar 

  33. Pongers-Willemse MJ, Verhagen OJ, Tibbe GJ, Wijkhuijs AJ, de Haas V, Roovers E, van der Schoot CE, van Dongen JJ . Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes Leukemia 1998 12: 2006–2014

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the SKK (grant 96.02). We thank Prof Dr JJM van Dongen and Prof Dr D Roos for critical reading of the manuscript.

Author information

Authors and Affiliations

  1. Emma Kinderziekenhuis AMC, University of Amsterdam, Amsterdam, The Netherlands

    V de Haas & H van den Berg

  2. Central Laboratory of the Netherlands Red Cross Blood Transfusion Service and Laboratory of Experimental and Clinical Immunology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands

    V de Haas, OJHM Verhagen & CE van der Schoot

  3. Department of Hematology, Academic Medical Centre, Amsterdam, The Netherlands

    AEGKr von dem Borne & CE van der Schoot

  4. Department of Cytogenetics, Academic Medical Centre, Amsterdam, The Netherlands

    W Kroes

Authors
  1. V de Haas
    View author publications

    Search author on:PubMed Google Scholar

  2. OJHM Verhagen
    View author publications

    Search author on:PubMed Google Scholar

  3. AEGKr von dem Borne
    View author publications

    Search author on:PubMed Google Scholar

  4. W Kroes
    View author publications

    Search author on:PubMed Google Scholar

  5. H van den Berg
    View author publications

    Search author on:PubMed Google Scholar

  6. CE van der Schoot
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

de Haas, V., Verhagen, O., von dem Borne, A. et al. Quantification of minimal residual disease in children with oligoclonal B-precursor acute lymphoblastic leukemia indicates that the clones that grow out during relapse already have the slowest rate of reduction during induction therapy. Leukemia 15, 134–140 (2001). https://doi.org/10.1038/sj.leu.2401970

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/sj.leu.2401970

Keywords

This article is cited by

Search

Advanced search

Quick links